# Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT

> **NCT04738981** · PHASE3 · COMPLETED · sponsor: **Peking University People's Hospital** · enrollment: 130 (actual)

## Conditions studied

- Graft Vs Host Disease

## Interventions

- **DRUG:** UC-MSC
- **DRUG:** Anti-CD25 mAb

## Key facts

- **NCT ID:** NCT04738981
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-01
- **Primary completion:** 2022-05-30
- **Final completion:** 2023-05-02
- **Target enrollment:** 130 (ACTUAL)
- **Last updated:** 2023-06-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04738981

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04738981, "Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04738981. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*